2021 Targeted Therapies of Lung Cancer (TTLC) Meeting - Posters-P09. Response to Standard Therapies and Comprehensive Genomic Analysis for Patients With Lung Adenocarcinoma With EGFR Exon 20 Insertions

P09. Response to Standard Therapies and Comprehensive Genomic Analysis for Patients With Lung Adenocarcinoma With EGFR Exon 20 Insertions

Back to course

Video Transcription

Video Summary

The presenter discusses the clinical outcomes and response to standard therapies for patients with EGFR Axon 20 insertions in non-small cell lung cancer. Compared to patients without targetable alterations, these patients had prolonged overall survival of 20 vs 12 months and prolonged time-to-treatment discontinuation on platinum chemotherapy. However, they did not derive additional benefit from immune checkpoint inhibitor therapy. Patients with EGFR Axon 20 insertions had a lower tumor mutational burden and a higher proportion of patients with PD-L1 expression less than 1%. It is suggested that molecularly targeted therapies would benefit these patients.

Asset Subtitle

Noura Choudhury

Meta Tag

Speaker Noura Choudhury

Topic Targeted Therapies - EGFR

Keywords

EGFR Axon 20 insertions

non-small cell lung cancer

clinical outcomes

standard therapies

overall survival